Shaily Engineering Plastics LimitedQ1 FY27 Results & Financial Update

Management believes Shaily holds a dominant or major market share position for generic pen launches in Canada (Number 1) and Brazil (Number 2), and anticipates leading positions in emerging expansion markets such as Mexico, Turkey, and the Middle East.

The company is advancing several new healthcare device platforms, including emergency use auto-injectors (targeting 99.999% reliability for molecules like epinephrine by end of FY27), reusable auto-injectors (showcasing at CPHI Milan), and on-body injectors for oncology (delivering 3 ml to 15 ml).

Shaily appointed senior industry leaders as dedicated business development heads for Europe and North America to drive engagement with innovator pharmaceutical brands and secure partnerships over the near term.

The company delivered close to 9 million delivery devices in Q1 FY27, with approximately 50% to 60% comprising GLP-1 therapies and the remainder consisting of insulin and other molecules.

Secured a global project from an FMCG customer, won new business in LED lighting, and was awarded 5 new complex internal components from a new Consumer Electronics customer for commercial supply starting before the end of the financial year.

An additional 25 million pen capacity is expected to become operational by the end of September 2026, bringing total installed pen injector capacity to approximately 75 million pens per annum.

The speed of the newly set-up pen line was increased by 9%, with plans for a further 30% jump upon receipt of additional equipment by the end of the quarter. For upcoming lines, the company has altered its strategy to achieve 80% plus efficiency at the supplier prior to factory acceptance testing (FAT) and shipping.

Planned capital expenditures include approximately INR5 crores for initial requirements in semiconductor trays at the existing facility, and an estimated investment of INR80 crores to INR100 crores for a southern plant dedicated to Consumer Electronics once finalized.

Management stated that its pen injector contracts are not cost-plus but intellectual property-led, market-driven volume agreements with annual price reviews based on base indices, inflation, and polymers. Against Chinese copycat GLP-1 pen offerings priced around $1.50 to $1.70, Shaily's pricing remains above the $2 mark.

Management expects gross margins to return to normalized levels by Q3 following the realization of delayed price pass-through actions implemented between May, June, and July.

A revenue drop observed in the UK subsidiary is attributed to a timing issue where milestone invoices are held until formal customer confirmation of milestone achievement is received; these revenues are expected to recover over the next three quarters.

Despite partner-specific supply chain issues, management expressed confidence in exceeding its full-year guidance of 36 million pen delivery devices, supported by growing efficiencies and strong underlying demand.

The Abu Dhabi facility is targeted to be in production by the end of FY28, supporting commercial sales for European market openings in 2028 and global insulin markets in 2030 and 2031.

Shaleen Kumar (UBS India) discussed Q1 delivery device volumes (~9 million pens) and the debottlenecking of the new manufacturing line, where management confirmed speeds improved by 9% with an anticipated 30% jump upon equipment installation by quarter-end.

Ritesh Shah (Investec) questioned the sequential gross margin decline alongside higher healthcare revenue contribution. Management cited rising commodity and freight costs and delayed price pass-throughs. Regarding Chinese competitors pricing at $1.50-$1.70, management noted Shaily's pricing remains above $2 and that competitor products involve older, potentially infringing technology.

Harshh Shah (JM Financial) and Nirali Gopani (Unique PMS) inquired about Consumer Electronics scaling and component complexity. Management stated that internal components supplied to the new customer are highly complex, with precision engineering requirements exceeding those of medical pen injectors, and targets reaching $10 million in revenue within 24 to 30 months.

Rupesh Tatiya (Long Equity Partners) asked about the complexity of semiconductor trays. Management explained that these are specialized consumables made from conductive plastics with critical dimensional tolerances, supplied globally by fewer than a dozen companies.

Aman Vij (Astute Investment Management) asked about customer feedback on commercialized pen devices in Brazil and Canada. Management reported above-average feedback with no statistical decline in batch testing data, and noted that additional partner launches over the next 2 to 3 quarters will drive further volume scaling.